(COO) The Cooper Companies - Overview
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US2166485019
Stock:
Total Rating 40
Risk 94
Buy Signal 0.11
| Risk 5d forecast | |
|---|---|
| Volatility | 25.0% |
| Relative Tail Risk | -10.1% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.15 |
| Alpha | -20.94 |
| Character TTM | |
|---|---|
| Beta | 0.714 |
| Beta Downside | 0.865 |
| Drawdowns 3y | |
|---|---|
| Max DD | 42.17% |
| CAGR/Max DD | 0.03 |
EPS (Earnings per Share)
Revenue
Description: COO The Cooper Companies
The Cooper Companies, Inc., together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment offers spherical, toric, and multifocal contact lenses that address vision challenges, such as astigmatism, presbyopia, and myopia. Its CooperSurgical segment focuses on family and women's health care, which provides fertility products and services, medical devices, and contraception, as well as cryostorage, such as cord blood and cord tissue storage. This segment offers Paragard, a hormone-free intrauterine device; and fertility consumables and equipment, donor gamete services, and genomic services, including genetic testing. The company sells its products to distributors, group purchasing organizations, eye care and health care professionals, including independent practices, corporate retailers, hospitals and clinics, and authorized resellers. The Cooper Companies, Inc. was founded in 1958 and is headquartered in San Ramon, California.
Piotroski VR‑10 (Strict, 0-10) 7.0
| Net Income: 374.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.03 > 0.02 and ΔFCF/TA 1.16 > 1.0 |
| NWC/Revenue: 24.28% < 20% (prev 23.84%; Δ 0.44% < -1%) |
| CFO/TA 0.06 > 3% & CFO 796.1m > Net Income 374.9m |
| Net Debt (2.67b) to EBITDA (1.02b): 2.62 < 3 |
| Current Ratio: 1.89 > 1.5 & < 3 |
| Outstanding Shares: last quarter (198.1m) vs 12m ago -1.49% < -2% |
| Gross Margin: 64.32% > 18% (prev 0.67%; Δ 6365 % > 0.5%) |
| Asset Turnover: 33.12% > 50% (prev 31.63%; Δ 1.49% > 0%) |
| Interest Coverage Ratio: 5.89 > 6 (EBITDA TTM 1.02b / Interest Expense TTM 109.1m) |
Altman Z'' 4.72
| A: 0.08 (Total Current Assets 2.11b - Total Current Liabilities 1.11b) / Total Assets 12.39b |
| B: 0.62 (Retained Earnings 7.64b / Total Assets 12.39b) |
| C: 0.05 (EBIT TTM 642.1m / Avg Total Assets 12.36b) |
| D: 1.75 (Book Value of Equity 7.26b / Total Liabilities 4.16b) |
| Altman-Z'' Score: 4.72 = AA |
Beneish M -2.93
| DSRI: 1.10 (Receivables 829.0m/717.0m, Revenue 4.09b/3.90b) |
| GMI: 1.04 (GM 64.32% / 66.64%) |
| AQI: 0.96 (AQ_t 0.66 / AQ_t-1 0.69) |
| SGI: 1.05 (Revenue 4.09b / 3.90b) |
| TATA: -0.03 (NI 374.9m - CFO 796.1m) / TA 12.39b) |
| Beneish M-Score: -2.93 (Cap -4..+1) = A |
What is the price of COO shares?
As of February 27, 2026, the stock is trading at USD 83.47 with a total of 1,974,019 shares traded.
Over the past week, the price has changed by +0.39%, over one month by +3.84%, over three months by +7.79% and over the past year by -7.67%.
Over the past week, the price has changed by +0.39%, over one month by +3.84%, over three months by +7.79% and over the past year by -7.67%.
Is COO a buy, sell or hold?
The Cooper Companies has received a consensus analysts rating of 4.05.
Therefore, it is recommended to buy COO.
- StrongBuy: 9
- Buy: 2
- Hold: 8
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the COO price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 91 | 9% |
| Analysts Target Price | 91 | 9% |
COO Fundamental Data Overview February 25, 2026
P/E Trailing = 44.3529
P/E Forward = 15.9744
P/S = 4.0292
P/B = 1.9998
P/EG = 0.8676
Revenue TTM = 4.09b USD
EBIT TTM = 642.1m USD
EBITDA TTM = 1.02b USD
Long Term Debt = 2.46b USD (from longTermDebt, last quarter)
Short Term Debt = 86.3m USD (from shortTermDebt, last quarter)
Debt = 2.78b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 2.67b USD (from netDebt column, last quarter)
Enterprise Value = 19.16b USD (16.49b + Debt 2.78b - CCE 110.6m)
Interest Coverage Ratio = 5.89 (Ebit TTM 642.1m / Interest Expense TTM 109.1m)
EV/FCF = 44.18x (Enterprise Value 19.16b / FCF TTM 433.7m)
FCF Yield = 2.26% (FCF TTM 433.7m / Enterprise Value 19.16b)
FCF Margin = 10.60% (FCF TTM 433.7m / Revenue TTM 4.09b)
Net Margin = 9.16% (Net Income TTM 374.9m / Revenue TTM 4.09b)
Gross Margin = 64.32% ((Revenue TTM 4.09b - Cost of Revenue TTM 1.46b) / Revenue TTM)
Gross Margin QoQ = 56.42% (prev 65.26%)
Tobins Q-Ratio = 1.55 (Enterprise Value 19.16b / Total Assets 12.39b)
Interest Expense / Debt = 0.88% (Interest Expense 24.4m / Debt 2.78b)
Taxrate = 27.57% (32.2m / 116.8m)
NOPAT = 465.1m (EBIT 642.1m * (1 - 27.57%))
Current Ratio = 1.89 (Total Current Assets 2.11b / Total Current Liabilities 1.11b)
Debt / Equity = 0.34 (Debt 2.78b / totalStockholderEquity, last quarter 8.24b)
Debt / EBITDA = 2.62 (Net Debt 2.67b / EBITDA 1.02b)
Debt / FCF = 6.16 (Net Debt 2.67b / FCF TTM 433.7m)
Total Stockholder Equity = 8.25b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.03% (Net Income 374.9m / Total Assets 12.39b)
RoE = 4.54% (Net Income TTM 374.9m / Total Stockholder Equity 8.25b)
RoCE = 6.00% (EBIT 642.1m / Capital Employed (Equity 8.25b + L.T.Debt 2.46b))
RoIC = 4.32% (NOPAT 465.1m / Invested Capital 10.78b)
WACC = 7.41% (E(16.49b)/V(19.27b) * Re(8.55%) + D(2.78b)/V(19.27b) * Rd(0.88%) * (1-Tc(0.28)))
Discount Rate = 8.55% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -0.38%
[DCF] Terminal Value 78.01% ; FCFF base≈375.5m ; Y1≈321.2m ; Y5≈249.0m
[DCF] Fair Price = 12.37 (EV 5.10b - Net Debt 2.67b = Equity 2.42b / Shares 196.0m; r=7.41% [WACC]; 5y FCF grow -17.55% → 2.90% )
EPS Correlation: -84.43 | EPS CAGR: -59.55% | SUE: -4.0 | # QB: 0
Revenue Correlation: 97.26 | Revenue CAGR: 8.40% | SUE: 0.30 | # QB: 0
EPS next Quarter (2026-04-30): EPS=1.07 | Chg7d=-0.002 | Chg30d=-0.001 | Revisions Net=+1 | Analysts=17
EPS current Year (2026-10-31): EPS=4.51 | Chg7d=-0.001 | Chg30d=-0.001 | Revisions Net=+0 | Growth EPS=+9.4% | Growth Revenue=+5.5%
EPS next Year (2027-10-31): EPS=4.96 | Chg7d=-0.002 | Chg30d=+0.012 | Revisions Net=+1 | Growth EPS=+10.0% | Growth Revenue=+5.4%
[Analyst] Revisions Ratio: +1.00 (1 Up / 0 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 6.3% (Discount Rate 8.6% - Earnings Yield 2.3%)
[Growth] Growth Spread = -1.3% (Analyst 5.0% - Implied 6.3%)
P/E Forward = 15.9744
P/S = 4.0292
P/B = 1.9998
P/EG = 0.8676
Revenue TTM = 4.09b USD
EBIT TTM = 642.1m USD
EBITDA TTM = 1.02b USD
Long Term Debt = 2.46b USD (from longTermDebt, last quarter)
Short Term Debt = 86.3m USD (from shortTermDebt, last quarter)
Debt = 2.78b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 2.67b USD (from netDebt column, last quarter)
Enterprise Value = 19.16b USD (16.49b + Debt 2.78b - CCE 110.6m)
Interest Coverage Ratio = 5.89 (Ebit TTM 642.1m / Interest Expense TTM 109.1m)
EV/FCF = 44.18x (Enterprise Value 19.16b / FCF TTM 433.7m)
FCF Yield = 2.26% (FCF TTM 433.7m / Enterprise Value 19.16b)
FCF Margin = 10.60% (FCF TTM 433.7m / Revenue TTM 4.09b)
Net Margin = 9.16% (Net Income TTM 374.9m / Revenue TTM 4.09b)
Gross Margin = 64.32% ((Revenue TTM 4.09b - Cost of Revenue TTM 1.46b) / Revenue TTM)
Gross Margin QoQ = 56.42% (prev 65.26%)
Tobins Q-Ratio = 1.55 (Enterprise Value 19.16b / Total Assets 12.39b)
Interest Expense / Debt = 0.88% (Interest Expense 24.4m / Debt 2.78b)
Taxrate = 27.57% (32.2m / 116.8m)
NOPAT = 465.1m (EBIT 642.1m * (1 - 27.57%))
Current Ratio = 1.89 (Total Current Assets 2.11b / Total Current Liabilities 1.11b)
Debt / Equity = 0.34 (Debt 2.78b / totalStockholderEquity, last quarter 8.24b)
Debt / EBITDA = 2.62 (Net Debt 2.67b / EBITDA 1.02b)
Debt / FCF = 6.16 (Net Debt 2.67b / FCF TTM 433.7m)
Total Stockholder Equity = 8.25b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.03% (Net Income 374.9m / Total Assets 12.39b)
RoE = 4.54% (Net Income TTM 374.9m / Total Stockholder Equity 8.25b)
RoCE = 6.00% (EBIT 642.1m / Capital Employed (Equity 8.25b + L.T.Debt 2.46b))
RoIC = 4.32% (NOPAT 465.1m / Invested Capital 10.78b)
WACC = 7.41% (E(16.49b)/V(19.27b) * Re(8.55%) + D(2.78b)/V(19.27b) * Rd(0.88%) * (1-Tc(0.28)))
Discount Rate = 8.55% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -0.38%
[DCF] Terminal Value 78.01% ; FCFF base≈375.5m ; Y1≈321.2m ; Y5≈249.0m
[DCF] Fair Price = 12.37 (EV 5.10b - Net Debt 2.67b = Equity 2.42b / Shares 196.0m; r=7.41% [WACC]; 5y FCF grow -17.55% → 2.90% )
EPS Correlation: -84.43 | EPS CAGR: -59.55% | SUE: -4.0 | # QB: 0
Revenue Correlation: 97.26 | Revenue CAGR: 8.40% | SUE: 0.30 | # QB: 0
EPS next Quarter (2026-04-30): EPS=1.07 | Chg7d=-0.002 | Chg30d=-0.001 | Revisions Net=+1 | Analysts=17
EPS current Year (2026-10-31): EPS=4.51 | Chg7d=-0.001 | Chg30d=-0.001 | Revisions Net=+0 | Growth EPS=+9.4% | Growth Revenue=+5.5%
EPS next Year (2027-10-31): EPS=4.96 | Chg7d=-0.002 | Chg30d=+0.012 | Revisions Net=+1 | Growth EPS=+10.0% | Growth Revenue=+5.4%
[Analyst] Revisions Ratio: +1.00 (1 Up / 0 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 6.3% (Discount Rate 8.6% - Earnings Yield 2.3%)
[Growth] Growth Spread = -1.3% (Analyst 5.0% - Implied 6.3%)